
Masterclasses in Dermatology
Visit the Masterclasses in Dermatology website: https://masterclassesindermatology.com/
Masterclasses in Dermatology offers interdisciplinary education tailored to dermatologists across a wide range of medical and surgical diseases featuring topics in novel imaging techniques, innovations, and advocacy.
Our multidisciplinary approach gathers experts from multiple therapeutic areas, e.g., gastroenterology, rheumatology, dermatology, surgery, and ophthalmology ...
read more ↘ to teach and interact with our dermatology practitioner audience and multi-disciplinary, pharmaceutical colleagues.
↖ read less
Masterclasses in Dermatology offers interdisciplinary education tailored to dermatologists across a wide range of medical and surgical diseases featuring topics in novel imaging techniques, innovations, and advocacy.
Our multidisciplinary approach gathers experts from multiple therapeutic areas, e.g., gastroenterology, rheumatology, dermatology, surgery, and ophthalmology ...
read more ↘ to teach and interact with our dermatology practitioner audience and multi-disciplinary, pharmaceutical colleagues.
↖ read less
- Masterclasses in Dermatology 2025
- Masterclasses in Psoriatic Disease APP+ 2024
- Masterclasses in Dermatology 2024
- Masterclasses in Psoriatic Disease APP+ 2023
- Masterclasses in Dermatology 2023
- Events
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
What's New in Atopic Dermatitis and Itch Treatment?
By
Masterclasses in Dermatology
FEATURING
Gil Yosipovitch
By
Masterclasses in Dermatology
FEATURING
Gil Yosipovitch
581 views
March 6, 2024
Disclaimer: On September 13, 2024, the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), ...
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less
Comments 2
Login to view comments.
Click here to Login
Masterclasses in Dermatology 2024